(TheNewswire)
Toronto, ON / TheNewswire / January 22,
2019 – Ventripoint Diagnostics Ltd.
(“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it has successfully received the Medical Device
Single Audit Program (MDSAP) certification, following an audit of its quality management system by our Notified Body/Registrar, an
authorized third party auditing organization.
The Medical Device Single Audit Program (MDSAP) became a mandatory requirement by Health Canada on
January 1, 2019 and allows the conduct of a single regulatory audit of a medical device manufacturer's quality management system
that satisfies the requirements of multiple regulatory jurisdictions, including Canada, United States, Japan, Brazil, and
Australia.
"We are very proud of this latest achievement, which solidifies Ventripoint’s abilities to continue to produce
and sell its VMS+ System globally and positions us at the forefront of quality assurance," commented Dr. Alvira Macanovic, PhD,
Ventripoint’s Director of Regulatory Affairs and Quality Assurance.
The MDSAP audit approach reduces the need for duplicate quality management audits, allowing device
manufacturers to better manage costs and ease global market access.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based
Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the
first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has
developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac
care.
For further information, please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing",
"may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking
information or statements. The forward-looking statements and information are based on certain key expectations and assumptions
made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and
information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking
statements and information address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other
factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most
recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com.
Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news
release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news
release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any
forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required
by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2019 TheNewswire - All rights reserved.